[go: up one dir, main page]

MX2022000489A - Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla. - Google Patents

Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla.

Info

Publication number
MX2022000489A
MX2022000489A MX2022000489A MX2022000489A MX2022000489A MX 2022000489 A MX2022000489 A MX 2022000489A MX 2022000489 A MX2022000489 A MX 2022000489A MX 2022000489 A MX2022000489 A MX 2022000489A MX 2022000489 A MX2022000489 A MX 2022000489A
Authority
MX
Mexico
Prior art keywords
long
rivastigmine
preparing
microsphere
sustained
Prior art date
Application number
MX2022000489A
Other languages
English (en)
Inventor
Heeyong Lee
Eunyoung Seol
Juhan Lee
Yeonkyeong Lee
Donghyun Park
Heekyoung Choe
Original Assignee
G2Gbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2Gbio Inc filed Critical G2Gbio Inc
Publication of MX2022000489A publication Critical patent/MX2022000489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a una microesfera de liberación sostenida para formulaciones inyectables de larga duración que comprenden uno o más ingredientes activos seleccionados del grupo que consiste de rivastigmina y sales deficientemente solubles farmacéuticamente aceptables de la misma y un polímero biodegradable, y una formulación inyectable de larga duración para prevenir o tratar enfermedad de Alzheimer que comprende la misma y un método para preparar la microesfera, y esta puede reducir los efectos secundarios del tracto gastrointestinal del paciente, que frecuentemente se observan en el agente de administración oral convencionales, e incrementar la adaptabilidad de la toma de medicina, para de esta manera maximizar el efecto terapéutico, al proporcionar una formulación inyectable de larga duración que comprende una microesfera de liberación sostenida de rivastigmina, que tiene un alto contenido mientras que controla de manera efectiva la liberación del fármaco repentina inicial.
MX2022000489A 2019-07-12 2020-07-13 Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla. MX2022000489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190084775 2019-07-12
PCT/KR2020/009221 WO2021010719A1 (ko) 2019-07-12 2020-07-13 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법

Publications (1)

Publication Number Publication Date
MX2022000489A true MX2022000489A (es) 2022-02-03

Family

ID=74211043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000489A MX2022000489A (es) 2019-07-12 2020-07-13 Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla.

Country Status (11)

Country Link
US (1) US20220257518A1 (es)
EP (1) EP3998065A4 (es)
JP (2) JP7437074B2 (es)
KR (4) KR20210007924A (es)
CN (1) CN114126592A (es)
AU (1) AU2020312361B2 (es)
BR (1) BR112022000413A2 (es)
CA (1) CA3143471C (es)
MX (1) MX2022000489A (es)
WO (1) WO2021010719A1 (es)
ZA (1) ZA202201465B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210158232A (ko) * 2020-06-23 2021-12-30 주식회사 아울바이오 치매치료를 위한 장기지속형 주사제
CN115124456B (zh) * 2021-03-26 2024-05-10 上海云晟研新生物科技有限公司 哌马色林药用盐、制备方法、含其的药物组合物及应用
CN113877000B (zh) * 2021-10-13 2023-01-24 科笛生物医药(无锡)有限公司 注射用微球组合物及其应用
WO2023249465A1 (ko) * 2022-06-23 2023-12-28 주식회사 지투지바이오 엔테카비르를 포함하는 장기지속성 미립구 제제 및 이의 제조방법
KR20240000405A (ko) * 2022-06-23 2024-01-02 주식회사 지투지바이오 약물과 파모산을 함유하는 서방성 미립구
KR20240115109A (ko) * 2023-01-18 2024-07-25 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
CN101563068B (zh) * 2006-12-18 2013-03-20 武田药品工业株式会社 缓释组合物和其制备方法
CA2743600C (en) * 2008-11-14 2016-11-08 Ewha University-Industry Collaboration Foundation Method for preparing microspheres and microspheres produced thereby
CN101708164A (zh) * 2009-12-18 2010-05-19 苏州大学 一种卡巴拉汀缓释微球及其制备方法
KR20120011344A (ko) * 2010-07-21 2012-02-08 에스케이케미칼주식회사 고분자 미립구의 제조방법 및 그 방법에 의해 제조된 고분자 미립구
KR101424163B1 (ko) 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
WO2013078608A1 (en) * 2011-11-29 2013-06-06 Ziqiang Gu Donepezil pamoate and methods of making and using the same
KR101307729B1 (ko) * 2012-11-19 2013-09-11 에스케이케미칼주식회사 초기 약물 방출이 감소된 고분자 미립자를 포함하는 주사용 조성물 및 이의 제조방법
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
WO2016198113A1 (en) * 2015-06-11 2016-12-15 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
KR101961848B1 (ko) * 2016-08-25 2019-03-25 영진약품 주식회사 C18:1, c18:1(oh) 또는 c18:2의 장쇄 지방산이 포함된 오일류를 포함한 방출억제제를 적용한 서방출성 마이크로스피어 및 이의 제조방법
KR101900482B1 (ko) 2017-01-17 2018-09-19 한국화학연구원 미립구형 서방출 주사제 및 그의 제조방법
WO2019045355A1 (ko) * 2017-08-29 2019-03-07 대원제약 주식회사 리바스티그민 파모산염의 제조방법
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법

Also Published As

Publication number Publication date
JP2022541011A (ja) 2022-09-21
BR112022000413A2 (pt) 2022-03-03
KR20220112737A (ko) 2022-08-11
US20220257518A1 (en) 2022-08-18
EP3998065A1 (en) 2022-05-18
KR102752744B1 (ko) 2025-01-10
AU2020312361A1 (en) 2022-03-03
KR20210007924A (ko) 2021-01-20
AU2020312361B2 (en) 2024-05-09
CN114126592A (zh) 2022-03-01
KR102752745B1 (ko) 2025-01-10
JP7437074B2 (ja) 2024-02-22
ZA202201465B (en) 2023-11-29
KR20210065921A (ko) 2021-06-04
CA3143471A1 (en) 2021-01-21
CA3143471C (en) 2023-10-31
EP3998065A4 (en) 2023-07-12
JP2024010233A (ja) 2024-01-23
KR20220044921A (ko) 2022-04-12
WO2021010719A1 (ko) 2021-01-21

Similar Documents

Publication Publication Date Title
MX2022000489A (es) Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla.
CN104968368A (zh) 固溶体组合物及其在剧痛中的用途
JP2018035171A (ja) 医薬製剤
CN110035757A (zh) 一种奥拉帕尼口服缓控释药物组合物及其用途
EP3323413B1 (en) Pharmaceutical composition containing celecoxib and tramadol
JP2014513124A (ja) 膣投与のための迅速溶解性錠剤組成物
CO5060477A1 (es) Forma de dosificacion de nefazodona
KR101156054B1 (ko) 안정한 에페리손 함유 서방성 의약조성물
US20220071988A1 (en) Sustained release buprenorphine microspheres (srbm) and methods of use thereof
US20240245713A1 (en) Long-acting injectable formulations and use thereof
ES2733649T3 (es) Formulación farmacéutica de liberación lenta
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
JP2021520400A (ja) エダラボン医薬組成物
JP2021500377A (ja) 遅延放出デフェリプロン錠剤及びその使用法
CN114555088A (zh) 包含赛乐西帕的药物组合物
JP6935393B2 (ja) セバコイルジナルブフィンエステルの徐放のための医薬製剤
Larrañeta et al. Overview of the clinical current needs and potential applications for long-acting and implantable delivery systems
US9968572B2 (en) Clonidine and GABA compounds in a biodegradable polymer carrier
KR101817028B1 (ko) 지속성 케토프로펜 조성물
TW200406200A (en) Pharmaceutical formulation
US20130217673A1 (en) Mixed monoamine reuptake inhibitor in a biodegradable polymer carrier
US20140107088A1 (en) Medical devices and methods comprising an anabolic agent for treatment of an injury
RU2021102950A (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
Pandya et al. Optimization and Evaluation of A formulation containing low soluble antihypertensive agent
ES2558204T3 (es) Formulaciones de comprimido bicapa de flurbiprofeno y glucosamina